
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
Statement issued by the company (Announcement) Io Therapeutics, Inc. in Spring, Texas, announces collaborative publication of data from preclinical studies with scientists at The University of Texas MD Anderson Cancer Center demonstrating effectiveness of the retinoid X receptor (RXR) agonist compound IRX4204 in models of prevention of estrogen receptor-negative and triple-negative breast cancers in three